Download PDF
Semin Liver Dis 2007; 27(2): 161-172
DOI: 10.1055/s-2007-979469
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Interpreting Serological Tests in Diagnosing Autoimmune Liver Diseases

Pietro Invernizzi1 , Ana Lleo1 , Mauro Podda1
  • 1Division of Internal Medicine and Liver Unit, San Paolo Hospital School of Medicine, University of Milan, Milan, Italy
Further Information

Publication History

Publication Date:
22 May 2007 (online)

    Permissions and Reprints

ABSTRACT

Autoimmune liver diseases (ALD) are characterized by immune-mediated injury of bile ducts or hepatocytes, thus including cholangiopathies such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis, and autoimmune hepatitis. Further, ALD variants manifesting with both hepatocellular and cholangiocellular damage are becoming more common. Serum autoantibodies, together with imaging and histology, are critical to the diagnostic process when ALD is suspected. Because an early diagnosis can influence prognosis, the development of sensitive and specific tests for serum autoantibodies should be a priority for researchers to ensure a more efficient noninvasive workup. Little prognostic value has been observed for any of the ALD serum hallmarks, and a vigorous effort to investigate new and old markers should therefore be undertaken in longitudinal studies as in the recent paradigm of PBC-specific antinuclear antibodies. We review herein the numerous ALD screening tests available in routine and specialized laboratories and comment on their significance in clinical practice.

KEYWORDS

Autoimmune hepatitis - primary biliary cirrhosis - primary sclerosing cholangitis - overlap syndromes - serum autoantibodies

REFERENCES

  • 1 Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis.  Semin Liver Dis. 2005;  25 298-310
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Beuers U, Rust C. Overlap syndromes.  Semin Liver Dis. 2005;  25 311-320
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Cowling D C, Mackay I R, Taft L I. Lupoid hepatitis.  Lancet. 1956;  271 1323-1326
    PubMedGoogle Scholar
  • 4 Krawitt E L. Autoimmune hepatitis.  N Engl J Med. 2006;  354 54-66
    CrossrefPubMedGoogle Scholar
  • 5 Homberg J C, Abuaf N, Bernard O et al.. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis.  Hepatology. 1987;  7 1333-1339
    PubMedGoogle Scholar
  • 6 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31 929-938
    CrossrefPubMedGoogle Scholar
  • 7 Johnson P J, McFarlane I G. Meeting report: International Autoimmune Hepatitis Group.  Hepatology. 1993;  18 998-1005
    CrossrefPubMedGoogle Scholar
  • 8 Burgart L J, Batts K P, Ludwig J, Nikias G A, Czaja A J. Recent-onset autoimmune hepatitis: biopsy findings and clinical correlations.  Am J Surg Pathol. 1995;  19 699-708
    PubMedGoogle Scholar
  • 9 Vergani D, Alvarez F, Bianchi F B et al.. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.  J Hepatol. 2004;  41 677-683
    CrossrefPubMedGoogle Scholar
  • 10 Strassburg C P, Manns M P. Autoantibodies and autoantigens in autoimmune hepatitis.  Semin Liver Dis. 2002;  22 339-352
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Hueber A J, Boxberger F, Ganslmayer M, Hahn E G. Antiphospholipid syndrome in combination with autoimmune hepatitis.  Eur J Gastroenterol Hepatol. 2005;  17 241-243
    CrossrefPubMedGoogle Scholar
  • 12 Muratori P, Muratori L, Guidi M et al.. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases.  Clin Exp Immunol. 2003;  132 473-476
    CrossrefPubMedGoogle Scholar
  • 13 Lyons R, Narain S, Nichols C, Satoh M, Reeves W H. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease.  Ann NY Acad Sci. 2005;  1050 217-228
    CrossrefPubMedGoogle Scholar
  • 14 Strassburg C P, Alex B, Zindy F et al.. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases.  J Hepatol. 1996;  25 859-866
    CrossrefPubMedGoogle Scholar
  • 15 Strassburg C P, Manns M P. Antinuclear antibody (ANA) patterns in hepatic and extrahepatic autoimmune disease.  J Hepatol. 1999;  31 751
    CrossrefPubMedGoogle Scholar
  • 16 Czaja A J, Nishioka M, Morshed S A, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis.  Gastroenterology. 1994;  107 200-207
    PubMedGoogle Scholar
  • 17 Czaja A J, Cassani F, Cataleta M, Valentini P, Bianchi F B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis.  Hepatology. 1996;  24 1068-1073
    CrossrefPubMedGoogle Scholar
  • 18 Bottazzo G F, Florin-Christensen A, Fairfax A et al.. Classification of smooth muscle autoantibodies detected by immunofluorescence.  J Clin Pathol. 1976;  29 403-410
    PubMedGoogle Scholar
  • 19 Gatselis N K, Georgiadou S P, Koukoulis G K et al.. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C.  Aliment Pharmacol Ther. 2006;  24 1563-1573
    CrossrefPubMedGoogle Scholar
  • 20 Muratori P, Muratori L, Agostinelli D et al.. Smooth muscle antibodies and type 1 autoimmune hepatitis.  Autoimmunity. 2002;  35 497-500
    CrossrefPubMedGoogle Scholar
  • 21 Czaja A J. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis.  J Hepatol. 1999;  30 394-401
    CrossrefPubMedGoogle Scholar
  • 22 Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde K H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen.  Lancet. 1987;  1 292-294
    PubMedGoogle Scholar
  • 23 Teufel M, Niessen K H, Berg P A. Chronic active hepatitis in childhood with detection of liver-pancreas-specific autoantibodies.  Eur J Pediatr. 1983;  140 30-33
    CrossrefPubMedGoogle Scholar
  • 24 Wies I, Brunner S, Henninger J et al.. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis.  Lancet. 2000;  355 1510-1515
    CrossrefPubMedGoogle Scholar
  • 25 Herkel J, Heidrich B, Nieraad N et al.. Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas.  Hepatology. 2002;  35 403-408
    CrossrefPubMedGoogle Scholar
  • 26 Ma Y, Okamoto M, Thomas M G et al.. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.  Hepatology. 2002;  35 658-664
    CrossrefPubMedGoogle Scholar
  • 27 Baeres M, Herkel J, Czaja A J et al.. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.  Gut. 2002;  51 259-264
    CrossrefPubMedGoogle Scholar
  • 28 Czaja A J, Donaldson P T, Lohse A W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis.  Am J Gastroenterol. 2002;  97 413-419
    CrossrefPubMedGoogle Scholar
  • 29 Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders.  Clin Exp Immunol. 1973;  15 331-344
    PubMedGoogle Scholar
  • 30 Muratori L, Lenzi M, Ma Y et al.. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease.  Gut. 1995;  37 406-412
    PubMedGoogle Scholar
  • 31 Yamamoto A M, Cresteil D, Homberg J C, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera.  Gastroenterology. 1993;  104 1762-1767
    PubMedGoogle Scholar
  • 32 Yamamoto A M, Johanet C, Duclos-Vallee J C et al.. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay.  Clin Exp Immunol. 1997;  108 396-400
    CrossrefPubMedGoogle Scholar
  • 33 Homberg J C, Abuaf N, Helmy-Khalil S et al.. Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies.  Hepatology. 1985;  5 722-727
    PubMedGoogle Scholar
  • 34 Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.  J Clin Invest. 1991;  88 1370-1378
    PubMedGoogle Scholar
  • 35 Manns M P, Vogel A. Autoimmune hepatitis, from mechanisms to therapy.  Hepatology. 2006;  43(suppl 1) S132-S144
    CrossrefPubMedGoogle Scholar
  • 36 Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens.  Hepatology. 2004;  39 1066-1074
    CrossrefPubMedGoogle Scholar
  • 37 Lenzi M, Manotti P, Muratori L et al.. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection.  Gut. 1995;  36 749-754
    PubMedGoogle Scholar
  • 38 Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi F B. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis.  Gut. 1998;  42 721-726
    CrossrefPubMedGoogle Scholar
  • 39 Lapierre P, Hajoui O, Homberg J C, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis.  Gastroenterology. 1999;  116 643-649
    PubMedGoogle Scholar
  • 40 Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases.  Semin Liver Dis. 1991;  11 215-222
    PubMedGoogle Scholar
  • 41 Treichel U, Gerken G, Rossol S et al.. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis.  J Hepatol. 1993;  19 55-63
    CrossrefPubMedGoogle Scholar
  • 42 Targan S R, Landers C, Vidrich A, Czaja A J. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis.  Gastroenterology. 1995;  108 1159-1166
    PubMedGoogle Scholar
  • 43 Kaplan M M, Gershwin M E. Primary biliary cirrhosis.  N Engl J Med. 2005;  353 1261-1273
    CrossrefPubMedGoogle Scholar
  • 44 Prince M I, Chetwynd A, Craig W L, Metcalf J V, James O F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.  Gut. 2004;  53 865-870
    CrossrefPubMedGoogle Scholar
  • 45 Mackay I R, Whittingham S, Fida S et al.. The peculiar autoimmunity of primary biliary cirrhosis.  Immunol Rev. 2000;  174 226-237
    CrossrefPubMedGoogle Scholar
  • 46 Gershwin M E, Ansari A A, Mackay I R et al.. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells.  Immunol Rev. 2000;  174 210-225
    CrossrefPubMedGoogle Scholar
  • 47 Invernizzi P, Crosignani A, Battezzati P M et al.. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.  Hepatology. 1997;  25 1090-1095
    CrossrefPubMedGoogle Scholar
  • 48 Heathcote E J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.  Hepatology. 2000;  31 1005-1013
    CrossrefPubMedGoogle Scholar
  • 49 Van de Water J, Cooper A, Surh C D et al.. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis.  N Engl J Med. 1989;  320 1377-1380
    PubMedGoogle Scholar
  • 50 Kitami N, Komada T, Ishii H et al.. Immunological study of anti-M2 in antimitochondrial antibody-negative primary biliary cirrhosis.  Intern Med. 1995;  34 496-501
    PubMedGoogle Scholar
  • 51 Mattalia A, Luttig B, Rosina F et al.. Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis.  J Autoimmun. 1997;  10 491-497
    CrossrefPubMedGoogle Scholar
  • 52 Oertelt S, Rieger R, Selmi C et al.. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis.  Hepatology. 2007;  45 659-665
    CrossrefPubMedGoogle Scholar
  • 53 Joshi S, Cauch-Dudek K, Heathcote E J et al.. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis'.  Am J Gastroenterol. 2002;  97 999-1002
    CrossrefPubMedGoogle Scholar
  • 54 Neuberger J, Bradwell A R. Anti-mitochondrial antibodies in primary biliary cirrhosis.  J Hepatol. 2002;  37 712-716
    CrossrefPubMedGoogle Scholar
  • 55 Muratori L, Muratori P, Granito A et al.. The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis.  Dig Liver Dis. 2005;  37 108-112
    CrossrefPubMedGoogle Scholar
  • 56 Ishibashi H, Shimoda S, Gershwin M E. The immune response to mitochondrial autoantigens.  Semin Liver Dis. 2005;  25 337-346
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Nishio A, Keeffe E B, Gershwin M E. Immunopathogenesis of primary biliary cirrhosis.  Semin Liver Dis. 2002;  22 291-302
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Metcalf J V, Mitchison H C, Palmer J M et al.. Natural history of early primary biliary cirrhosis.  Lancet. 1996;  348 1399-1402
    CrossrefPubMedGoogle Scholar
  • 59 Invernizzi P, Podda M, Battezzati P M et al.. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis.  J Hepatol. 2001;  34 366-372
    CrossrefPubMedGoogle Scholar
  • 60 Muratori P, Muratori L, Ferrari R et al.. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.  Am J Gastroenterol. 2003;  98 431-437
    CrossrefPubMedGoogle Scholar
  • 61 Rigopoulou E I, Davies E T, Pares A et al.. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.  Gut. 2005;  54 528-532
    CrossrefPubMedGoogle Scholar
  • 62 Yang W H, Yu J H, Nakajima A et al.. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure'.  Clin Gastroenterol Hepatol. 2004;  2 1116-1122
    CrossrefPubMedGoogle Scholar
  • 63 Itoh S, Ichida T, Yoshida T et al.. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.  J Gastroenterol Hepatol. 1998;  13 257-265
    CrossrefPubMedGoogle Scholar
  • 64 Miyachi K, Hankins R W, Matsushima H et al.. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study.  J Autoimmun. 2003;  20 247-254
    CrossrefPubMedGoogle Scholar
  • 65 Invernizzi P, Wesierska-Gadek J, Battezzati P M et al.. Prognostic value of autoantibodies against proteins of nuclear pore complexes (anti-NPCs) in early primary biliary cirrhosis (PBC).  J Hepatol. 2004;  40 159-160. Abstract
    PubMedGoogle Scholar
  • 66 Wesierska-Gadek J, Penner E, Battezzati P M et al.. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.  Hepatology. 2006;  43 1135-1144
    CrossrefPubMedGoogle Scholar
  • 67 Nakamura M, Shimizu-Yoshida Y, Takii Y et al.. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.  J Hepatol. 2005;  42 386-392
    CrossrefPubMedGoogle Scholar
  • 68 Nakamura M, Kondo H, Mori T et al.. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.  Hepatology. 2007;  45 118-127
    CrossrefPubMedGoogle Scholar
  • 69 Dickson E R, Grambsch P M, Fleming T R, Fisher L D, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making.  Hepatology. 1989;  10 1-7
    PubMedGoogle Scholar
  • 70 Heathcote J. Autoimmune cholangitis.  Gut. 1997;  40 440-442
    PubMedGoogle Scholar
  • 71 Czaja A J, Carpenter H A, Santrach P J, Moore S B. Autoimmune cholangitis within the spectrum of autoimmune liver disease.  Hepatology. 2000;  31 1231-1238
    CrossrefPubMedGoogle Scholar
  • 72 Lee Y M, Kaplan M M. Primary sclerosing cholangitis.  N Engl J Med. 1995;  332 924-933
    CrossrefPubMedGoogle Scholar
  • 73 Cullen S N, Chapman R W. The medical management of primary sclerosing cholangitis.  Semin Liver Dis. 2006;  26 52-61
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Lazaridis K N, Gores G J. Primary sclerosing cholangitis and cholangiocarcinoma.  Semin Liver Dis. 2006;  26 42-51
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis.  Clin Rev Allergy Immunol. 2005;  28 93-103
    PubMedGoogle Scholar
  • 76 Aoki C A, Bowlus C L, Gershwin M E. The immunobiology of primary sclerosing cholangitis.  Autoimmun Rev. 2005;  4 137-143
    CrossrefPubMedGoogle Scholar
  • 77 Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis.  Semin Liver Dis. 1991;  11 31-39
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer.  Semin Liver Dis. 2006;  26 31-41
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Wiencke K, Spurkland A, Schrumpf E, Boberg K M. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles.  Hepatology. 2001;  34 625-630
    PubMedGoogle Scholar
  • 80 O'Mahony C A, Vierling J M. Etiopathogenesis of primary sclerosing cholangitis.  Semin Liver Dis. 2006;  26 3-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 81 Mayer L. Redefining autoimmunity.  Gastroenterology. 2003;  125 1574
    CrossrefPubMedGoogle Scholar
  • 82 Hamano H, Kawa S, Horiuchi A et al.. High serum IgG4 concentrations in patients with sclerosing pancreatitis.  N Engl J Med. 2001;  344 732-738
    CrossrefPubMedGoogle Scholar
  • 83 Mendes F D, Jorgensen R, Keach J et al.. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis.  Am J Gastroenterol. 2006;  101 2070-2075
    CrossrefPubMedGoogle Scholar
  • 84 Levy C, Lindor K D. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis.  Semin Liver Dis. 2006;  26 22-30
    Article in Thieme ConnectPubMedGoogle Scholar
  • 85 Mieli-Vergani G, Vergani D. Immunological liver diseases in children.  Semin Liver Dis. 1998;  18 271-279
    PubMedGoogle Scholar
  • 86 Gross W L, Ludemann G, Kiefer G, Lehmann H. Anticytoplasmic antibodies in Wegener's granulomatosis.  Lancet. 1986;  1 806
    PubMedGoogle Scholar
  • 87 Jenne D E, Tschopp J, Ludemann J, Utecht B, Gross W L. Wegener's autoantigen decoded.  Nature. 1990;  346 520
    PubMedGoogle Scholar
  • 88 Peen E, Sundqvist T, Skogh T. Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium.  Clin Exp Immunol. 1996;  103 403-407
    PubMedGoogle Scholar
  • 89 Seibold F, Weber P, Klein R, Berg P A, Wiedmann K H. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.  Gut. 1992;  33 657-662
    PubMedGoogle Scholar
  • 90 Duerr R H, Targan S R, Landers C J et al.. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.  Gastroenterology. 1991;  100 1385-1391
    PubMedGoogle Scholar
  • 91 Mulder A H, Broekroelofs J, Horst G et al.. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates.  Clin Exp Immunol. 1994;  95 490-497
    PubMedGoogle Scholar
  • 92 Terjung B, Herzog V, Worman H J et al.. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins.  Hepatology. 1998;  28 332-340
    CrossrefPubMedGoogle Scholar
  • 93 Terjung B, Worman H J. Anti-neutrophil antibodies in primary sclerosing cholangitis.  Best Pract Res Clin Gastroenterol. 2001;  15 629-642
    CrossrefPubMedGoogle Scholar
  • 94 Terjung B, Spengler U, Sauerbruch T, Worman H J. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.  Gastroenterology. 2000;  119 310-322
    CrossrefPubMedGoogle Scholar
  • 95 Roozendaal C, de Jong M A, van den Berg A P et al.. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases.  J Hepatol. 2000;  32 734-741
    CrossrefPubMedGoogle Scholar
  • 96 Angulo P, Peter J B, Gershwin M E et al.. Serum autoantibodies in patients with primary sclerosing cholangitis.  J Hepatol. 2000;  32 182-187
    PubMedGoogle Scholar
  • 97 Xu B, Broome U, Ericzon B G, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.  Gut. 2002;  51 120-127
    CrossrefPubMedGoogle Scholar
  • 98 Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage.  Cancer Sci. 2004;  95 930-935
    CrossrefPubMedGoogle Scholar
  • 99 Naor D, Nedvetzki S. CD44 in rheumatoid arthritis.  Arthritis Res Ther. 2003;  5 105-115
    PubMedGoogle Scholar
  • 100 Beuers U. Hepatic overlap syndromes.  J Hepatol. 2005;  42(suppl 1) S93-S99
    CrossrefPubMedGoogle Scholar
  • 101 Czaja A J. The variant forms of autoimmune hepatitis.  Ann Intern Med. 1996;  125 588-598
    PubMedGoogle Scholar
  • 102 Kaya M, Angulo P, Lindor K D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system.  J Hepatol. 2000;  33 537-542
    CrossrefPubMedGoogle Scholar
  • 103 Chazouilleres O. Diagnosis of primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: to score or not to score'.  J Hepatol. 2000;  33 661-663
    CrossrefPubMedGoogle Scholar
  • 104 Gregorio G V, Portmann B, Karani J et al.. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.  Hepatology. 2001;  33 544-553
    CrossrefPubMedGoogle Scholar
  • 105 Vignali D A. Multiplexed particle-based flow cytometric assays.  J Immunol Methods. 2000;  243 243-255
    CrossrefPubMedGoogle Scholar

Pietro InvernizziM.D. Ph.D. 

Division of Internal Medicine and Liver Unit, San Paolo Hospital School of Medicine, University of Milan

Via di Rudinì 8, 20142 Milano, Italy